The news means around 1,700 people with kidney cancer in England will have a new treatment option, and signifies an important landmark in the treatment landscape, representing the first approval of an immuno-oncology combination therapy for first-line patients with this type of cancer in England.
American drug-maker Bristol-Myers Squibb announced that the immunotherapy combination is to be immediately available via the Cancer Drugs Fund, based on data from a Phase III head-to-head study, which was stopped early due to an overall survival efficacy benefit versus sunitinib, a current standard of care.
The Phase III CheckMate 214 study consisted of 1096 patients, and found a 37% decreased risk of death in intermediate and poor-prognostic risk patients, as well as an objective response rate of 42% and complete response rate of 9%.
“It’s very good news that the combination of nivolumab and ipilimumab has now been approved for use in patients with intermediate- and poor risk advanced renal cell carcinoma. A study has demonstrated that this immunotherapy combination is superior to sunitinib in extending overall survival and may now benefit patients whose lives are threatened by a cancer that has increased in incidence by nearly 50% in the last decade,” said Dr Paul Nathan, consultant medical oncologist at Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust…